ロード中...

Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA) process, invited the manufacturer of pomalidomide (POM; Imnovid(®), Celgene) to submit evidence regarding the clinical and cost effectiveness of the drug in combination with dex...

詳細記述

保存先:
書誌詳細
出版年:Pharmacoeconomics
主要な著者: Büyükkaramikli, Nasuh C., de Groot, Saskia, Fayter, Debra, Wolff, Robert, Armstrong, Nigel, Stirk, Lisa, Worthy, Gill, Albuquerque de Almeida, Fernando, Kleijnen, Jos, Al, Maiwenn J.
フォーマット: Artigo
言語:Inglês
出版事項: Springer International Publishing 2017
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5805808/
https://ncbi.nlm.nih.gov/pubmed/29086363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-017-0581-6
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!